MR, ST, ES-B, MB, SL, SM, AOS, JP, KP, HB, KD, and MLR are employees of the Henry M. The authors thank the participants, investigators, and sponsors of the HVTN 505 trial.Ĭompeting interests: The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, the US Department of Defense or the Department of the Army. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The work is made available under the Creative Commons CC0 public domain dedication.ĭata Availability: Sequences are available under GenBank accession numbers MG196642 - MG197219.įunding: Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under award numbers R37AI054165 and UM1AI068635.
Identifies sequences free#
This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Received: MaAccepted: SeptemPublished: November 17, 2017 PLoS ONE 12(11):Įditor: Zhiwei Chen, University of Hong Kong, HONG KONG (2017) Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. These results suggest either (i) no vaccine efficacy to block acquisition of any viral genotype but vaccine-accelerated Env evolution post-acquisition or (ii) vaccine efficacy against HIV-1s with Env sequences closest to the vaccine insert combined with increased acquisition due to other factors, potentially including the vaccine vector.Ĭitation: deCamp AC, Rolland M, Edlefsen PT, Sanders-Buell E, Hall B, Magaret CA, et al. These vaccine effects were associated with signatures mapping to CD4 binding site and CD4-induced monoclonal antibody footprints. Furthermore, Env-gp120 sequences from vaccine recipients were significantly more distant from the subtype B vaccine insert than sequences from placebo recipients (P = 0.01, Q-value = 0.12). We analyzed 480 HIV-1 genomes sampled from 27 vaccine and 20 placebo recipients and found that intra-host HIV-1 diversity was significantly lower in vaccine recipients (P ≤ 0.04, Q-values ≤ 0.09) in Gag, Pol, Vif and envelope glycoprotein gp120 (Env-gp120).
Identifies sequences trial#
Although the HVTN 505 DNA/recombinant adenovirus type 5 vector HIV-1 vaccine trial showed no overall efficacy, analysis of breakthrough HIV-1 sequences in participants can help determine whether vaccine-induced immune responses impacted viruses that caused infection.
0 kommentar(er)
